Should I buy or sell Clearside Biomedical stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLSD shares. View CLSD analyst ratings or view top-rated stocks .

What is Clearside Biomedical's stock price target for 2024?

4 equities research analysts have issued twelve-month price targets for Clearside Biomedical's shares. Their CLSD share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.75 in the next year. This suggests a possible upside of 261.2% from the stock's current price. View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts .

How have CLSD shares performed in 2024?

Clearside Biomedical's stock was trading at $1.17 at the beginning of 2024. Since then, CLSD shares have increased by 12.4% and is now trading at $1.3150. View the best growth stocks for 2024 here .

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a drop in short interest in March. As of March 31st, there was short interest totaling 224,300 shares, a drop of 34.0% from the March 15th total of 339,900 shares. Based on an average trading volume of 353,400 shares, the days-to-cover ratio is presently 0.6 days. View Clearside Biomedical's Short Interest .

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CLSD earnings forecast .

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The business had revenue of $6.35 million for the quarter, compared to the consensus estimate of $3.40 million.

What other stocks do shareholders of Clearside Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO) , Ocular Therapeutix (OCUL) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Melinta Therapeutics (MLNT) , Organigram (OGI) , Zosano Pharma (ZSAN) , Sorrento Therapeutics (SRNE) , Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE) .

When did Clearside Biomedical IPO?

Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different institutional and retail investors. Top institutional shareholders include International Assets Investment Management LLC (0.05%). Insiders that own company stock include Anthony S Gibney, Bradford T Whitmore, Bradford T Whitmore , Charles A Deignan , Clay Thorp, George M Lasezkay , Nancy J Hutson, Ngai Hang Victor Chong, Richard T Burke and Thomas Ciulla . View institutional ownership trends .

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CLSD

Clearside Biomedical (CLSD) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CLSD Stock Alerts

$1.31

-0.01 (-0.76%)

(As of 04:00 PM ET)

Compare

Today's Range: $1.25
▼
$1.45
50-Day Range: $1.15
▼
$2.02
52-Week Range: $0.65
▼
$2.12

Volume: 227,275 shs
Average Volume: 343,706 shs
Market Capitalization: $97.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.75

Get Clearside Biomedical alerts:

Clearside Biomedical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 261.2% Upside
$4.75 Price Target
Short Interest: Healthy
0.30% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.56
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$656,387 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.56) to ($0.51) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

Medical Sector

363rd out of 918 stocks

Biotechnology Industry

9th out of 29 stocks

3.5

Analyst's Opinion

Consensus Rating
Clearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Clearside Biomedical has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.30% of the outstanding shares of Clearside Biomedical have been sold short.
Short Interest Ratio / Days to Cover
Clearside Biomedical has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Clearside Biomedical has recently decreased by 34.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Clearside Biomedical does not currently pay a dividend.
Dividend Growth
Clearside Biomedical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLSD.

2.0

News and Social Media Coverage

News Sentiment
Clearside Biomedical has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Clearside Biomedical this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CLSD on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clearside Biomedical insiders have bought 1,567.14% more of their company's stock than they have sold. Specifically, they have bought $656,387.00 in company stock and sold $39,372.00 in company stock.
Percentage Held by Insiders
Only 9.80% of the stock of Clearside Biomedical is held by insiders.
Percentage Held by Institutions
Only 18.75% of the stock of Clearside Biomedical is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Clearside Biomedical are expected to grow in the coming year, from ($0.56) to ($0.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Clearside Biomedical is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clearside Biomedical is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Clearside Biomedical Stock (NASDAQ:CLSD)

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CLSD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLSD Stock News Headlines

March 21, 2024 | insidertrades.com

Ngai Hang Victor Chong Buys 30,000 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) Stock

April 17, 2024 | americanbankingnews.com

Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by Analysts

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | globenewswire.com

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

April 13, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)

April 2, 2024 | globenewswire.com

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

March 18, 2024 | globenewswire.com

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

March 14, 2024 | markets.businessinsider.com

Clearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial Progress

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 14, 2024 | finance.yahoo.com

Clearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

March 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Clearside Biomedical on Innovative Treatments and Strong Financials

March 13, 2024 | finance.yahoo.com

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript

March 12, 2024 | benzinga.com

Clearside Biomedical: Q4 Earnings Insights

March 12, 2024 | finance.yahoo.com

Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...

March 12, 2024 | globenewswire.com

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 11, 2024 | benzinga.com

Preview: Clearside Biomedical's Earnings

March 1, 2024 | finance.yahoo.com

Clearside Biomedical, Inc. (CLSD)

February 29, 2024 | globenewswire.com

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

February 25, 2024 | investorplace.com

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

February 21, 2024 | markets.businessinsider.com

ModivCare is about to announce its earnings — here's what Wall Street expects

February 21, 2024 | benzinga.com

Clearside Biomedical Stock (NASDAQ:CLSD), Short Interest Report

February 18, 2024 | finance.yahoo.com

CLSD Apr 2024 5.000 call

February 9, 2024 | msn.com

Clearside Biomedical Launches $15M Direct Offering

February 9, 2024 | msn.com

Clearside Biomedical Announces Registered Direct Offering Pricing

February 9, 2024 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Clearside Biomedical Stock

February 7, 2024 | finance.yahoo.com

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

December 15, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Clearside Biomedical Amidst Strong Clinical Progress and Strategic Partnerships

See More Headlines

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:CLSD
CUSIP: N/A
CIK: 1539029
Web: www.clearsidebio.com
Phone: (678) 270-3631
Fax: 678-270-4033
Employees: 30
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.75
High Stock Price Target: $6.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +262.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,490,000.00
Net Margins: -394.91%
Pretax Margin: -394.91%
Return on Equity: N/A
Return on Assets: -85.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.42
Quick Ratio: 4.42

Sales & Book Value

Annual Sales: $8.23 million
Price / Sales: 11.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.25) per share
Price / Book: -5.24

Miscellaneous

Outstanding Shares: 74,720,000
Free Float: 67,398,000
Market Cap: $97.88 million
Optionable: Optionable
Beta: 2.29

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. George M. Lasezkay J.D. (Age 72)
Pharm.D., Pharma.D., President, CEO & Director
Comp: $816.4k
Mr. Charles A. Deignan (Age 60)
Chief Financial Officer
Comp: $536.95k
Dr. Thomas A. Ciulla M.B.A. (Age 59)
M.D., Chairman of Scientific Advisory Board
Comp: $597.21k
Ms. Jenny R. Kobin (Age 57)
Head of Investor Relations
Mr. Rick McElheny
Vice President of Corporate Development
Mr. Rafael V. Andino (Age 59)
Senior Vice President of Engineering & Manufacturing
Ms. Susan L. Coultas Ph.D.
Chief Clinical Officer
Dr. Ngai Hang Chong M.B.A.
M.D., Chief Medical Officer
Mr. Leslie B. Zacks (Age 55)
Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLSD Stock Analysis - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings or view top-rated stocks.
What is Clearside Biomedical's stock price target for 2024?: 4 equities research analysts have issued twelve-month price targets for Clearside Biomedical's shares. Their CLSD share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.75 in the next year. This suggests a possible upside of 261.2% from the stock's current price.
View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts.
How have CLSD shares performed in 2024?: Clearside Biomedical's stock was trading at $1.17 at the beginning of 2024. Since then, CLSD shares have increased by 12.4% and is now trading at $1.3150.
View the best growth stocks for 2024 here.
Are investors shorting Clearside Biomedical?: Clearside Biomedical saw a drop in short interest in March. As of March 31st, there was short interest totaling 224,300 shares, a drop of 34.0% from the March 15th total of 339,900 shares. Based on an average trading volume of 353,400 shares, the days-to-cover ratio is presently 0.6 days.
View Clearside Biomedical's Short Interest.
When is Clearside Biomedical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CLSD earnings forecast.
How were Clearside Biomedical's earnings last quarter?: Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The business had revenue of $6.35 million for the quarter, compared to the consensus estimate of $3.40 million.

What other stocks do shareholders of Clearside Biomedical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).
When did Clearside Biomedical IPO?: Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Who are Clearside Biomedical's major shareholders?: Clearside Biomedical's stock is owned by many different institutional and retail investors. Top institutional shareholders include International Assets Investment Management LLC (0.05%). Insiders that own company stock include Anthony S Gibney, Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Ngai Hang Victor Chong, Richard T Burke and Thomas Ciulla.
View institutional ownership trends.
How do I buy shares of Clearside Biomedical?: Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLSD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial